Interferon alpha kinoid

Drug Profile

Interferon alpha kinoid

Alternative Names: Antiferon; IFN-K - Neovacs; IFNα kinoid

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Neovacs
  • Developer Neovacs; sanofi pasteur
  • Class Interferons; Vaccines
  • Mechanism of Action Immunomodulators; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Systemic lupus erythematosus
  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic lupus erythematosus

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus; Viral infections
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 07 Dec 2016 Interferon alpha kinoid receives Fast Track designation for Systemic lupus erythematosus [IM,Injection] in USA
  • 15 Nov 2016 Neovacs in-licenses interferon alpha manufacturing license from Amegabiotech
  • 07 Nov 2016 Phase-II clinical trials in Systemic lupus erythematosus in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top